BOSTON--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; ...

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from a debate at Lymphoma, Leukemia & Myeloma ...

—Adding data on lymphoma in adolescents and young adults may help improve the standardization of treatment and improve patient outcomes. Although cancer in adolescents and young adults (AYAs) is ...

MONTREAL, Oct. 21, 2024 /CNW/ - AbbVie (ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or ...

For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that 1 ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of waveLINE-010, a pivotal Phase 3 clinical trial evaluating ...

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester ...

Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

Diffuse large B-cell lymphoma is a common type of non-Hodgkin’s lymphoma that also has a high rate of relapse. Common signs of a relapse include lymph node swelling, as well as the development of “B ...